Yahoo
    NasdaqGS - Nasdaq Real Time Price USD

    Pharvaris N.V. (PHVS)

    33.53 -0.05 (-0.15%)
    At close: October 30 at 4:00:00 PM EDT
    34.00 +0.47 (+1.40%)
    After hours: October 30 at 4:25:26 PM EDT
    Trade PHVS on Coinbase
    Chart Range Bar
    Advanced Chart
    AlphaSpace Chart
    Loading chart for PHVS
    • Previous Close 33.58
    • Open 33.48
    • Bid 24.33 x 200
    • Ask 42.48 x 200
    • Day's Range 33.10 - 33.94
    • 52 Week Range 21.02 - 43.25
    • Volume 1,481,527
    • Avg. Volume 802,064
    • Market Cap (intraday) 2.354B
    • Beta (5Y Monthly) -2.46
    • PE Ratio (TTM) --
    • EPS (TTM) -3.06
    • Earnings Date (est.) Nov 12, 2026
    • Forward Dividend & Yield -- (0.00%)
    • 1y Target Est 57.49
    • Zacks Rating Neutral

    Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.

    pharvaris.com

    148

    Full Time Employees

    December 31

    Fiscal Year Ends

    Healthcare

    Sector

    Biotechnology

    Industry

    More about Pharvaris N.V.

    Recent News

    View More
    View More

    Performance Overview

    Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

    YTD Return

    PHVS
    20.83%
    S&P 500 (^GSPC)
    10.73%

    1-Year Return

    PHVS
    50.76%
    S&P 500 (^GSPC)
    11.11%

    3-Year Return

    PHVS
    97.70%
    S&P 500 (^GSPC)
    81.91%

    5-Year Return

    PHVS
    92.37%
    S&P 500 (^GSPC)
    64.59%

    Earnings Trends

    View More

    Earnings Per Share

    GAAP
    Normalized
    GAAP
    Normalized

    Revenue vs. Earnings

    Annual
    Quarterly
    Annual
    Quarterly
    Q2 FY26
    Revenue --
    Earnings -47.84M
    Profit Margin 0.00%

    Q2

    FY25

    Q3

    FY25

    Q4

    FY25

    Q2

    FY26

    -40M
    -30M
    -20M
    -10M
    0
    0.0%
    View More

    Analyst Insights

    View More

    Analyst Price Targets

    40.89
    57.49 Average
    33.53 Current
    78.78 High

    Analyst Recommendations

    • Strong Buy
    • Buy
    • Hold
    • Underperform
    • Sell

    Latest Rating

    Date 10/23/2026
    Analyst B of A Securities
    Rating Action Upgrade
    Rating Buy
    Price Action Maintains
    Price Target 44 -> 44
    View More

    Statistics

    View More

    Valuation Measures

    Annual

    • Market Cap

    • Enterprise Value

    • Trailing P/E

    • Forward P/E

    • PEG Ratio (current)

    • Price/Sales (ttm)

    • Price/Book (mrq)

    • Enterprise Value/Revenue

    • Enterprise Value/EBITDA

    Financial Highlights

    Profitability and Income Statement

    • Profit Margin

      0.00%

    • Return on Assets (ttm)

      -42.32%

    • Return on Equity (ttm)

      -70.46%

    • Revenue (ttm)

      --

    • Net Income Avi to Common (ttm)

      -170.92M

    • Diluted EPS (ttm)

      -3.06

    Balance Sheet and Cash Flow

    • Total Cash (mrq)

      318.28M

    • Total Debt/Equity (mrq)

      0.22%

    • Levered Free Cash Flow (ttm)

      -90.36M

    View More

    Company Insights

    Research Reports

    View More
    View More

    People Also Watch

    EWTX
    CGEM
    IMCR
    ORIC
    TYRA
    Mobilize your Website
    View Site in Mobile | Classic
    Share by: